WO2008107862A3 - Utilisation de ngf pour la préparation de médicaments destinés à traiter la gliose réactive - Google Patents

Utilisation de ngf pour la préparation de médicaments destinés à traiter la gliose réactive Download PDF

Info

Publication number
WO2008107862A3
WO2008107862A3 PCT/IB2008/050864 IB2008050864W WO2008107862A3 WO 2008107862 A3 WO2008107862 A3 WO 2008107862A3 IB 2008050864 W IB2008050864 W IB 2008050864W WO 2008107862 A3 WO2008107862 A3 WO 2008107862A3
Authority
WO
WIPO (PCT)
Prior art keywords
cure
ngf
preparation
medicaments
reactive gliosis
Prior art date
Application number
PCT/IB2008/050864
Other languages
English (en)
Other versions
WO2008107862A2 (fr
Inventor
Michele Papa
Original Assignee
Inbios S R L
Michele Papa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inbios S R L, Michele Papa filed Critical Inbios S R L
Publication of WO2008107862A2 publication Critical patent/WO2008107862A2/fr
Publication of WO2008107862A3 publication Critical patent/WO2008107862A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de NGF pour la préparation d'un médicament pour traiter et/ou prévenir la gliose réactive et des procédés thérapeutiques pour traiter et/ou prévenir la gliose réactive par administration de NGF.
PCT/IB2008/050864 2007-03-08 2008-03-10 Utilisation de ngf pour la préparation de médicaments destinés à traiter la gliose réactive WO2008107862A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2007A000119 2007-03-08
IT000119A ITRM20070119A1 (it) 2007-03-08 2007-03-08 Udo del ngf per la preparazione di mendicamenti per la cura della gliosi reattiva

Publications (2)

Publication Number Publication Date
WO2008107862A2 WO2008107862A2 (fr) 2008-09-12
WO2008107862A3 true WO2008107862A3 (fr) 2008-11-13

Family

ID=39522996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/050864 WO2008107862A2 (fr) 2007-03-08 2008-03-10 Utilisation de ngf pour la préparation de médicaments destinés à traiter la gliose réactive

Country Status (2)

Country Link
IT (1) ITRM20070119A1 (fr)
WO (1) WO2008107862A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036607A1 (fr) * 1996-03-29 1997-10-09 The Regents Of The University Of California Derives de peptides de synthese presentant une activite neurotrophique de type facteur de croissance nerveuse
US20030032589A1 (en) * 1998-04-08 2003-02-13 Ilse Bartke NGF for the prevention of demyelination in the nervous system
WO2003030836A2 (fr) * 2001-10-12 2003-04-17 Case Western Reserve University Regeneration neuronale
US20060247165A1 (en) * 2005-01-21 2006-11-02 Stupp Samuel I Methods and compositions for encapsulation of cells
EP1734052A1 (fr) * 2005-06-13 2006-12-20 Primm S.R.L. Peptides héterodimères ayant une activité de NGF et leur utilisation pour le traitement des maladies neurodegéneratives
WO2007034266A1 (fr) * 2005-09-23 2007-03-29 Blueprint Biotech Srl MÉTHODE POUR PRODUIRE DU rhNGF BIOLOGIQUEMENT ACTIF

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036607A1 (fr) * 1996-03-29 1997-10-09 The Regents Of The University Of California Derives de peptides de synthese presentant une activite neurotrophique de type facteur de croissance nerveuse
US20030032589A1 (en) * 1998-04-08 2003-02-13 Ilse Bartke NGF for the prevention of demyelination in the nervous system
WO2003030836A2 (fr) * 2001-10-12 2003-04-17 Case Western Reserve University Regeneration neuronale
US20060247165A1 (en) * 2005-01-21 2006-11-02 Stupp Samuel I Methods and compositions for encapsulation of cells
EP1734052A1 (fr) * 2005-06-13 2006-12-20 Primm S.R.L. Peptides héterodimères ayant une activité de NGF et leur utilisation pour le traitement des maladies neurodegéneratives
WO2007034266A1 (fr) * 2005-09-23 2007-03-29 Blueprint Biotech Srl MÉTHODE POUR PRODUIRE DU rhNGF BIOLOGIQUEMENT ACTIF

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIANCO MARIA ROSARIA ET AL: "A new Nerve Growth Factor (NGF)-mimetic peptide reduces gliosis and is active on neuropathic pain in rats", NEURON GLIA BIOLOGY, vol. 2, no. Suppl. 1, 2007, & 8TH EUROPEAN MEETING ON GLIAL CELLS IN HEALTH AND DISEASE; LONDON, UK; SEPTEMBER 04 -08, 2007, pages S144 - S145, XP009105254, ISSN: 1740-925X *
LABOURDETTE GERARD ET AL: "Gliosis growth factors in the adult and aging rat brain", CONTEMPORARY NEUROSCIENCE. NEUROGLIA IN THE AGING BRAIN HUMANA PRESS INC. {A}, 999 RIVERVIEW DRIVE, SUITE 208, TOTOWA, NJ, 07512, USA, 2002, pages 157 - 178, XP009105258, ISSN: 0-89603-594-8 *
OUDEGA M ET AL: "Nerve growth factor promotes regeneration of sensory axons into adult rat spinal cord", EXPERIMENTAL NEUROLOGY 199608 US, vol. 140, no. 2, August 1996 (1996-08-01), pages 218 - 229, XP009105293, ISSN: 0014-4886 *
SILVER J ET AL: "Regeneration beyond the glial scar", NATURE REVIEWS NEUROSCIENCE 200402 GB, vol. 5, no. 2, February 2004 (2004-02-01), pages 146 - 156, XP009105260, ISSN: 1471-003X *
SUN XIAODONG ET AL: "Nerve growth factor helps protect retina in experimental retinal detachment", OPHTHALMOLOGICA, vol. 222, no. 1, 2008, pages 58 - 61, XP009105253, ISSN: 0030-3755 *

Also Published As

Publication number Publication date
WO2008107862A2 (fr) 2008-09-12
ITRM20070119A1 (it) 2008-09-09

Similar Documents

Publication Publication Date Title
WO2009065406A3 (fr) Nouveaux composés hydrocarbonés cycliques pour le traitement de maladies
WO2009008001A3 (fr) Dispositif d'inhalation
WO2010014690A3 (fr) Dispositifs médicaux permettant l'administration d'un agent thérapeutique
HK1189181A1 (zh) 給予患者藥用氣體的系統
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL196028A (en) Hydroxy and toxic derivatives of cyclopenta [d] pyrimidine, including pharmaceutical preparations and their uses for medical treatment, including treatment and prevention of hyperproliferative disorders
WO2012016698A3 (fr) Forme galénique et pharmaceutique comprenant 6'-fluoro-(n-méthyl- or n,n-diméthyl-)-4-phényl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine pour le traitement de la douleur neuropathique
IL213407A (en) Use of combinations of drug factors to prepare combination therapy drugs
EP2273975B8 (fr) Solutions pharmaceutiques, procédé de préparation et utilisations thérapeutiques
WO2007121913A3 (fr) Formulations en solution pharmaceutiques pour aérosols-doseurs pressurisés
WO2010042471A3 (fr) Dispositifs médicaux pour administration d'agents thérapeutiques à des lumières corporelles
IL193727A0 (en) Dosage forms for administering combinations of drugs
EP1981527A4 (fr) Administration thermiquement ciblee de medicaments comme la doxorubicine
WO2009023311A9 (fr) Apport transcutané d'agents thérapeutiques
WO2012016845A3 (fr) Formulation pharmaceutique comprenant un inhibiteur de phosphodiestérase
WO2012010669A3 (fr) Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique
WO2009045543A8 (fr) Traitement d'affections liées à un choc
EP2241310A3 (fr) Formulations à libération modifiée d'émoxypine
WO2009003719A3 (fr) Dérivés d'indane-amine, leur préparation et leur utilisation comme médicaments
WO2011055383A3 (fr) Administration intranasale pour améliorer les performances d'enfants souffrant de dyslexie
WO2010012459A3 (fr) Procédé de préparation de sels de solifénacine et inclusion de ces derniers dans des formes pharmaceutiques
WO2009013010A3 (fr) Ligands 5ht6 dans un gain de poids induit par un médicament
WO2007098967A3 (fr) Composés ciblant les récepteurs sigma
EP1981569A4 (fr) Administration sans aiguille de dose unique de medicaments antithrombotiques
WO2009080745A3 (fr) Dérivés de perhydrochinoxaline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719625

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08719625

Country of ref document: EP

Kind code of ref document: A2